Full Press Release Details
MONTREAL and CHARLOTTE, May 06, 2026 (GLOBE NEWSWIRE) -- Milestone®Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will report financial results for the first quarter ended March 31, 2026, and provide a business update before the market open. The announcement will be followed by a conference call and webcast for investors at 8:30am ET.
Conference Details:
| Conference Date: | Wednesday, May 13, 2026 |
| Conference Time: | 8:30am ET |
| Conference Dial-in: | 1-877-407-0792 |
| International Dial-in: | 1-201-689-8263 |
| Conference ID: | 13760062 |
| Webcast link: | Clickhere. |
Participants can use Guest dial-in numbers above and be answered by an operator OR click theCall me™link for instant telephone access to the event. The Call me™ link will be made active 15 minutes prior to scheduled start time.
A replay of the audio webcast of the call will be available under the News & Events section of Milestone's website,www.milestonepharma.com.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is an emerging commercial-stage biopharmaceutical company advancing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST™ (etripamil) nasal spray, a novel calcium channel blocker, which is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in development for the control of symptomatic episodic attacks associated with AFib-RVR.
Contact:
Investor Relations
Kevin Gardner,kgardner@lifesciadvisors.com
Media Relations
Rebecca Novak,rnovak@milestonepharma.com